Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al

Affiliations

• ¹ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
• ² Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
• ³ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
• ⁴ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
• ⁵ Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
• ⁶ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
• ⁷ The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
• ⁸ Department of Neurological Surgery, Northwestern University, Chicago, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
• ⁹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
• ¹⁰ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
• ¹¹ Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
• ¹² Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.